Literature DB >> 11286609

Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial.

S A Ahmadi-Abhari1, S Akhondzadeh, S M Assadi, O L Shabestari, Z M Farzanehgan, A Kamlipour.   

Abstract

OBJECTIVE: Baclofen is known for the alleviation of signs and symptoms of spasticity. Reports from our previous study have suggested that it may be at least as effective as clonidine in the management of physical symptoms of opiate withdrawal syndromes and superior to clonidine in the management of mental symptoms. We now report on a randomized double-blind comparison of baclofen vs. clonidine in view of side-effects profile.
METHODS: A total of 62 opiates addicts were randomly assigned to treatment with baclofen or clonidine during a 14-day, double-blind clinical trial. All patients met the DSM IV criteria for opioid dependence. Maximum daily doses were 40 mg for baclofen and 0.8 mg for clonidine. This trial medication was given three times per day in divided doses. The severity of side-effects was measured in days 0, 1, 2, 3, 4, 7 and 14.
RESULTS: There was no significant difference between two treat7ments in terms of retention in treatment (dropout) and overall side-effect. Nevertheless, significantly more problems relating to hypotension were encountered with subjects on clonidine.
CONCLUSION: We conclude that, the low incidence of hypotension with baclofen suggests that the drug may be suitable for outpatient ambulatory treatment of withdrawal from opiates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286609     DOI: 10.1046/j.1365-2710.2001.00325.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  9 in total

1.  Dexmedetomidine for acute baclofen withdrawal.

Authors:  Simon Morr; Christopher M Heard; Veetai Li; Renée M Reynolds
Journal:  Neurocrit Care       Date:  2015-04       Impact factor: 3.210

2.  Regulation of gene expression by chronic morphine and morphine withdrawal in the locus ceruleus and ventral tegmental area.

Authors:  Colleen A McClung; Eric J Nestler; Venetia Zachariou
Journal:  J Neurosci       Date:  2005-06-22       Impact factor: 6.167

3.  FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment-a pharmacokinetic-pharmacodynamic study.

Authors:  L M Paterson; D Barker; S Cro; P Mozgunov; R Phillips; C Smith; L Nahar; S Paterson; A R Lingford-Hughes
Journal:  Trials       Date:  2022-10-18       Impact factor: 2.728

Review 4.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03

Review 5.  Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

Authors:  George F Koob; G Kenneth Lloyd; Barbara J Mason
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

6.  GABAB Receptors and Drug Addiction: Psychostimulants and Other Drugs of Abuse.

Authors:  Xiaofan Li; Paul A Slesinger
Journal:  Curr Top Behav Neurosci       Date:  2022

7.  Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder-An Animal Model and a Human Study.

Authors:  Tzofnat Bareli; Hadas Levi Ahdoot; Hilla Ben Moshe; Royi Barnea; Gal Warhaftig; Iris Gispan; Rachel Maayan; Paola Rosca; Abraham Weizman; Gal Yadid
Journal:  Front Behav Neurosci       Date:  2021-12-23       Impact factor: 3.558

8.  Opioid and GABAB receptors differentially couple to an adenylyl cyclase/protein kinase A downstream effector after chronic morphine treatment.

Authors:  Elena E Bagley
Journal:  Front Pharmacol       Date:  2014-06-24       Impact factor: 5.810

Review 9.  The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective.

Authors:  Renaud de Beaurepaire; Julia M A Sinclair; Mathis Heydtmann; Giovanni Addolorato; Henri-Jean Aubin; Esther M Beraha; Fabio Caputo; Jonathan D Chick; Patrick de La Selle; Nicolas Franchitto; James C Garbutt; Paul S Haber; Philippe Jaury; Anne R Lingford-Hughes; Kirsten C Morley; Christian A Müller; Lynn Owens; Adam Pastor; Louise M Paterson; Fanny Pélissier; Benjamin Rolland; Amanda Stafford; Andrew Thompson; Wim van den Brink; Lorenzo Leggio; Roberta Agabio
Journal:  Front Psychiatry       Date:  2019-01-04       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.